Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Bioscience (RCUS) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies targeting cancer’s immunosuppressive mechanisms. This page provides investors and researchers with timely updates on the company’s developments in immuno-oncology, including advancements in its ATP-adenosine pathway research.
Access the latest press releases, clinical trial milestones, and financial disclosures in one centralized hub. Track updates on therapeutic candidates spanning small molecules and biologics, partnership announcements, and regulatory progress. Our curated news collection ensures you stay informed about RCUS’s efforts to address unmet needs in lung, colorectal, and pancreatic cancers.
Bookmark this page for real-time insights into Arcus Bioscience’s R&D pipeline, strategic initiatives, and industry positioning. Check back regularly for verified updates directly from corporate communications and trusted financial sources.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focusing on cancer therapies, has announced new employment inducement grants. The company's Compensation Committee has approved equity awards for three new employees, including:
- Options to purchase 39,750 shares at $8.11 per share (closing price on April 23, 2025)
- Restricted stock units (RSUs) to acquire 19,950 shares
These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS) has announced the upcoming presentation of groundbreaking combination therapy data at the 2025 ASCO Annual Meeting. The presentation will feature results from the Phase 1/1b ARC-20 study evaluating their HIF-2a inhibitor casdatifan in combination with cabozantinib for clear cell renal cell carcinoma (ccRCC).
Dr. Toni Choueiri from Dana-Farber Cancer Institute will present safety and initial efficacy data for the combination of 100mg casdatifan once-daily with 60mg cabozantinib in patients previously treated with immunotherapy. The oral presentation is scheduled for June 1, 2025, during the Genitourinary Cancer session.
The company will host a conference call to discuss the ARC-20 data on June 2, 2025, at 5:00 AM PT. This data supports Arcus's development program, including their Phase 3 PEAK-1 trial and clinical collaboration with AstraZeneca to evaluate casdatifan with volrustomig in immuno-oncology-naive ccRCC patients.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company developing cancer therapies, has scheduled a conference call and webcast for Tuesday, May 6th, 2025, at 1:30 PM PT / 4:30 PM ET. The event will cover the company's financial results and pipeline updates for Q1 2025, ending March 31st.
Investors can join via phone at +1 (404) 975-4839 (local) or +1 (833) 470-1428 (toll-free) using Access Code: 762544, or register online. The webcast and presentation will be available in the Investors & Media section of arcusbio.com, with a replay available after the event.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to six new employees. The Compensation Committee approved stock options for 16,960 shares at an exercise price of $7.04 per share, reflecting the closing price on April 8, 2025. Additionally, the employees received restricted stock units totaling 8,530 shares. These equity awards were issued under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapies, has announced new employment inducement grants. The company's Compensation Committee has approved equity awards for twelve new employees, consisting of:
- Options to purchase 42,920 shares of common stock at $9.12 per share (closing price on March 24, 2025)
- Restricted stock units (RSUs) for 21,650 shares of common stock
These equity awards were granted under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in two major healthcare investor conferences in March 2025.
The company will attend the Leerink Global Healthcare Conference on March 12th, 2025, and the Barclays 27th Annual Global Healthcare Conference on March 13th, 2025. Both events will take place in Miami Beach, FL, featuring fireside chats and one-on-one meetings scheduled for 8:00 a.m. ET.
Investors can access live webcasts of these presentations through the Investors & Media section of www.arcusbio.com, with replay options available after the events.
Arcus Biosciences (NYSE:RCUS) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its cancer therapy pipeline. The company's lead drug casdatifan showed promising results in Phase 1/1b ARC-20 study for clear cell renal cell carcinoma (ccRCC), with over 30% confirmed overall response rate in two cohorts and favorable safety profile.
Key financial metrics include:
- Cash position of $992 million as of December 31, 2024
- Q4 2024 revenues of $36 million
- R&D expenses increased to $111 million in Q4 2024
- Net loss of $94 million in Q4 2024
The company plans to initiate the Phase 3 PEAK-1 study evaluating casdatifan with cabozantinib in H1 2025, with initial combination data expected mid-2025. Arcus completed a $150 million financing and expects current funding to support pivotal trials through initial readouts.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee has granted equity awards to one new employee. The grants include options to purchase 5,550 shares of common stock at an exercise price of $11.07 per share, which matched the closing price on February 21, 2025. Additionally, the employee received restricted stock units to acquire 2,800 shares of common stock. These equity awards were issued under the company's 2020 Inducement Plan, which was established in January 2020 under the NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.
Arcus Biosciences (NYSE:RCUS) has retained full rights to casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma (ccRCC), following the expiration of Gilead Sciences' option window. The company has also priced a $150 million common stock offering with participation from new and existing investors, including Gilead.
New data from the ARC-20 study showed improvements in progression rates, overall response rate (ORR), and progression-free survival (PFS) for casdatifan monotherapy. The company estimates a $5 billion market opportunity for this treatment. Key upcoming milestones include the initiation of the Phase 3 PEAK-1 trial in Q2 2025 and a clinical collaboration with AstraZeneca to evaluate casdatifan in combination with their anti-PD-1/CTLA-4 bispecific antibody.
Arcus Biosciences (NYSE:RCUS) has announced the pricing of an underwritten public offering of 13,636,364 shares of common stock at $11.00 per share, aiming to raise approximately $150 million in gross proceeds. The offering is expected to close around February 19, 2025.
The company plans to use the net proceeds to fund ongoing research and development activities, including the clinical development of casdatifan, manufacturing-related costs, and other general corporate purposes. Goldman Sachs, Leerink Partners, and Evercore ISI are serving as joint book-running managers for the offering.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
